Biotech Values

[mcbio]

As part of the cost-cutting maneuvers announced today, PFE will phase out drug development in allergy, respiratory, urology, tissue repair, and internal medicine.

Need to re-visit this one more time Dew. ; ) Presumably pain drugs wouldn't be covered in any of the above categories (namely 'internal medicine' as that strikes me as kind of a broad category) would they? Just thinking about the partnership ICGN has with PFE for its sodium channel pain drug and wondering if it could be on the chopping block.